| Literature DB >> 30937475 |
Y Bachour1, M J P F Ritt2, R Heijmans3, F B Niessen2, S P Verweij3.
Abstract
INTRODUCTION: The etiology of capsular contracture after surgical implantation of breast implants remains unclear, but an important role is seen for the immune system. Toll-like receptors are immune receptors recognizing both pathogen-associated molecular patterns and damage-associated molecular patterns. The former are present on bacteria such as Staphylococcus epidermidis (bacteria earlier associated with capsular contracture), and the latter are released after (mechanical) stress. The aim of this study was to investigate the expression of TLRs 1-10 in relation to capsular contracture.Entities:
Keywords: Breast augmentation; Breast implants; Capsular contracture; Etiology; Immunology; Toll-like receptors
Mesh:
Substances:
Year: 2019 PMID: 30937475 PMCID: PMC6652164 DOI: 10.1007/s00266-019-01368-8
Source DB: PubMed Journal: Aesthetic Plast Surg ISSN: 0364-216X Impact factor: 2.326
Fig. 1TLR cascade
Definition of baker grade I–IV
| Baker grade | Breast description |
|---|---|
| I | Breast absolutely normal: soft to palpate, implant not palpable or visible |
| II | Minimal contracture: greater breast firmness than desired, implant palpable, but not visible |
| III | Moderate contracture; moderate breast firmness, implant easily palpable, breast deformity visible |
| IV | Severe contracture: severe breast firmness, hard, painful/tender, distortion marked, and sometimes a cold implant |
Number of negative and positive tests in Baker 1–4 breast capsules using the Chi-square test
| TLR | Baker 1 ( | Baker 2 ( | Baker 3 ( | Baker 4 ( | |||||
|---|---|---|---|---|---|---|---|---|---|
| Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | ||
| 1 | 9 (75.0) | 3 (25.0) | 12 (75.0) | 4 (25.0) | 7 (70.0) | 3 (30.0) | 7 (58.3) | 5 (41.7) | NS |
| 2 | 6 (50.0) | 6 (50.0) | 15 (93.7) | 1 (6.3) | 6 (60.0) | 4 (40.0) | 6 (50.0) | 6 (50.0) | S* |
| 3 | 5 (41.7) | 7 (58.3) | 5 (31.3) | 11 (68.7) | 4 (40.0) | 6 (60.0) | 1 (8.3) | 11 (91.7) | NS |
| 4 | 6 (50.0) | 6 (50.0) | 10 (62.5) | 6 (37.5) | 5 (50.0) | 5 (50.0) | 5 (41.7) | 7 (58.3) | NS |
| 5 | 6 (50.0) | 6 (50.0) | 9 (56.3) | 7 (43.7) | 5 (50.0) | 5 (50.0) | 2 (16.7) | 10 (83.3) | NS |
| 6 | 4 (33.3) | 8 (66.7) | 11 (68.7) | 5 (31.3) | 1 (10.0) | 9 (90.0) | 3 (25.0) | 9 (75.0) | S** |
| 7 | 2 (16.7) | 10 (83.3) | 4 (25.0) | 12 (75.0) | 4 (40.0) | 6 (60.0) | 4 (33.3) | 8 (66.7) | NS |
| 8 | 2 (16.7) | 10 (83.3) | 10 (62.5) | 6 (37.5) | 5 (50.0) | 5 (50.0) | 7 (58.3) | 5 (41.7) | S*** |
| 9 | 1 (8.3) | 11 (91.7) | 4 (25.0) | 12 (75.0) | 1 (10.0) | 9 (90.0) | 2 (16.7) | 10 (83.3) | NS |
| 10 | 5 (57.1) | 7 (42.9) | 11 (68.7) | 5 (31.3) | 3 (30.0) | 7 (70.0) | 3 (25.0) | 9 (75.0) | NS |
Outcomes were considered positive when the automated threshold (e.g., a fluorescent intensity above background level) was met
NS not significant, S significant
*Baker 1 versus 2 (p = 0.008), Baker 2 versus 3 (p = 0.034)
**Baker 2 versus 3 (p = 0.003)
***Baker 1 versus 2 (p = 0.015), Baker 1 versus 4 (p = 0.035)
Mean concentration cDNA (copies/µlcDNA) in Baker 1–4 breast capsules using the Mann–Whitney U test
| TLR | Baker 1 ( | Baker 2 ( | Baker 3 ( | Baker 4 ( | |
|---|---|---|---|---|---|
| 1 | 0.8 (1.9) | 0.1 (0.2) | 0.3 (0.5) | 0.6 (1.2) | NS |
| 2 | 0.3 (0.5) | 0.6 (2.4) | 0.3 (0.7) | 1.0 (2.1) | S* |
| 3 | 2.6 (2.7) | 9.7 (27.6) | 4.5 (4.0) | 8.4 (7.8) | NS |
| 4 | 3.2 (5.2) | 2.0 (5.4) | 1.2 (1.5) | 2.2 (2.5) | NS |
| 5 | 1.7 (2.4) | 1.9 (6.3 | 1.1 (1.6) | 2.6 (2.5) | NS |
| 6 | 3.7 (4.2) | 3.6 (11.7) | 3.0 (3.0) | 3.6 (4.0) | S** |
| 7 | 1.9 (1.6) | 1.9 (5.0) | 2.0 (2.9) | 1.8 (3.1) | NS |
| 8 | 0.6 (0.6) | 0.2 (0.4) | 0.3 (0.4) | 0.2 (0.4) | S*** |
| 9 | 4.3 (3.8) | 5.3 (10.7) | 3.4 (3.3) | 3.1 (3.0) | NS |
| 10 | 2.1 (6.5) | 2.0 (6.5) | 0.9 (1.3) | 1.1 (1.5) | NS |
NS not significant, S significant
*Baker 1 versus 2 (p = 0.017)
**Baker 1 versus 2 (p = 0.049), Baker 2 versus 3 (p = 0.021)
***Baker 1 versus 2 (p = 0.018)